PT  - JOURNAL ARTICLE
AU  - Mona Issabakhsh
AU  - Rafael Meza
AU  - Yameng Li
AU  - Zhe Yuan
AU  - Luz Maria Sanchez-Romero
AU  - David T. Levy
TI  - The Public Health Impact of a US Menthol Cigarette Ban on the Non-Hispanic Black Population: A Simulation Study
AID  - 10.1101/2022.02.04.22270475
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.02.04.22270475
4099  - http://medrxiv.org/content/early/2022/02/06/2022.02.04.22270475.short
4100  - http://medrxiv.org/content/early/2022/02/06/2022.02.04.22270475.full
AB  - Introduction As the US Food and Drug Administration (FDA) evaluates implementing a ban on menthol cigarettes and cigars, it is critical to estimate the potential public health effects of such a ban. With high rates of menthol cigarette use by the non-Hispanic Black (NHB) population and important smoking-related health disparity implications, the impact of the ban on this population merits strong consideration.Methods We apply the previously developed Menthol Smoking and Vaping Model. A Status Quo Scenario is developed using population, smoking and vaping data specific to the NHB population. Estimates from a recent expert elicitation on behavioral impacts of a menthol cigarette ban on the NHB population are used to develop a Menthol Ban Scenario implemented in 2021. The public health impacts of the menthol ban are estimated as the difference between smoking and vaping attributable deaths (SVADs) and life years lost (LYLs) in the Status Quo and the Menthol Ban Scenarios from 2021-2060.Results Under the Menthol Ban Scenario, overall smoking is projected to decline by 35.1% in 2026, and by 24.0% in 2060 relative to the Status Quo Scenario. With these reductions, SVADs are estimated to fall by about 18.5% and LYLs by 22.1%, translating to 255,000 premature deaths averted, and 3.9 million life-years gained over a 40-year period.Conclusions A menthol cigarette ban will substantially reduce the smoking-associated health impact on the NHB population thereby reducing health disparities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the NIH and FDAAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The source data are openly available and can be obtained from public websitesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors